Tirzepatide: uses, evidence and status

compound file

The answer, first. A once-weekly dual GIP and GLP-1 receptor agonist developed by Eli Lilly, on the market since 2022 as Mounjaro and since 2023 as Zepbound. The strongest evidence is for chronic weight management, graded A — approval or replicated trials. Approved indication.

SURMOUNT-1: 20.9% lost at 15 mg vs 3.1% on placebo ¹. 57% lost at least 20% ¹. Beat semaglutide head-to-head in SURMOUNT-5, 20.2% vs 13.7% ².

What it is used for

Every use graded on its own evidence, not the compound as a whole. 5 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Chronic weight managementSURMOUNT-1, n=2,539, 72 weeks · superseded by the human recordgrade AApproved indication. SURMOUNT-1: 20.9% lost at 15 mg vs 3.1% on placebo ¹. 57% lost at least 20% ¹. Beat semaglutide head-to-head in SURMOUNT-5, 20.2% vs 13.7% ².

02Type 2 diabetes glycemic controlSURPASS program, phase 3 · superseded by the human recordgrade AApproved as Mounjaro. SURPASS-2: HbA1c fell 2.30 points at 15 mg vs 1.86 on semaglutide 1 mg over 40 weeks, n=1,879 ³.

03Obstructive sleep apnea in obesitySURMOUNT-OSA, two 52-week RCTs · superseded by the human recordgrade AApproved December 2024. The apnea-hypopnea index fell 25.3 and 29.3 events per hour across the two trials vs 5.3 and 5.5 on placebo at week 52 ⁴.

04Heart failure with preserved ejection fractionSUMMIT, n=731 · superseded by the human recordgrade BSUMMIT: cardiovascular death or worsening heart failure in 9.9% vs 15.3% on placebo over a median 104 weeks, hazard ratio 0.62 ⁵. One trial. Not on the approved label ¹⁰.

05MASH with fibrosisphase 2, n=190 · superseded by the human recordgrade CSYNERGY-NASH: MASH resolved without fibrosis worsening in 44 to 62% across doses vs 10% on placebo at week 52 ⁶. Phase 2 only. Larger trials still needed.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetA single 39-amino-acid peptide built on the GIP backbone, agonist at both GIP and GLP-1 receptors, with a C20 fatty-diacid albumin anchor ¹⁰.

2signalIncretin signalling on two fronts: glucose-dependent insulin secretion rises, glucagon falls, gastric emptying slows, central appetite circuits engage ¹⁰.

3effectBody weight fell 20.9% at 72 weeks in obesity ¹. HbA1c fell 2.30 points at 15 mg in type 2 diabetes ³.

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

Muscle-sparing weight loss. SURMOUNT-1 DXA substudy, n=160: about 25% of the weight lost was lean mass ⁷.
Results that last after stopping. SURMOUNT-4: after switching to placebo, participants regained 14.0% of body weight in a year while continuers kept losing ⁸.
Superior cardiovascular protection. SURPASS-CVOT, n=13,299: noninferior to dulaglutide on major events. Superiority not shown ⁹.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeOnce-weekly subcutaneous injection in abdomen, thigh or upper arm ¹⁰.

formatSingle-dose pens and vials as the approved product. Lyophilized gray-market vials otherwise.

published dosesZepbound label: 2.5 mg weekly for 4 weeks, then 2.5 mg steps at intervals of at least 4 weeks ¹⁰. Maintenance is 5, 10 or 15 mg, with 10 or 15 mg named for sleep apnea ¹⁰. SURMOUNT-1 randomized 5, 10 and 15 mg ¹.

human pharmacokineticsElimination half-life about 5 to 6 days ¹⁰. Dosing is once weekly.

reported conventionsAs reported on r/tirzepatidecompound, r/Zepbound and peptide forums, 2023-2026: compounding-era and gray-market vials dosed on the label ladder. 2.5 mg starts, four-week holds, many staying at 5 to 7.5 mg. Units are drawn on insulin syringes. Convention, not guidance.

commonly paired withCagrilintide

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetSURMOUNT-1: weight fell from the first weeks on every dose and kept falling to week 72, reaching 15.0 to 20.9% down ¹. The label ladder takes at least 20 weeks to reach 15 mg ¹⁰.

most common reportAs reported: appetite suppression from the first one or two injections. Nausea clusters around each dose step.

adverse effectsSURMOUNT-1: gastrointestinal events most common, mostly mild to moderate, concentrated in escalation ¹. Adverse events stopped treatment in 4.3 to 7.1% on drug vs 2.6% on placebo ¹. SURPASS-2: nausea 17 to 22%, diarrhea 13 to 16%, vomiting 6 to 10% ³.

the stop signalLabel: discontinue for suspected pancreatitis ¹⁰. Contraindicated with personal or family medullary thyroid carcinoma or MEN2 history ¹⁰. As reported: vomiting that outlasts an escalation step is the community stop signal.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalFDA-approved as Mounjaro [2022, diabetes] and Zepbound [2023 for weight, 2024 for obstructive sleep apnea]. EMA-approved.

FDAApproved products only. FDA declared the shortage resolved in December 2024, closing mass compounding. Research-market vials are unapproved, and GLP-1 imports face default detention under Import Alert 66-80.

sport [WADA]Not on the WADA Prohibited List. GLP-1 agonists are not banned in sport.

sold asapproved medicine

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is Tirzepatide used for?

Three approved lanes: chronic weight management, type 2 diabetes, and obstructive sleep apnea in obesity ¹³⁴.

Beyond the label, one well-powered trial supports benefit in heart failure with preserved ejection fraction ⁵ and a phase 2 trial in MASH ⁶. It is the benchmark the class is measured against: 20.9% lost in SURMOUNT-1, and a head-to-head win over semaglutide ¹².

How is Tirzepatide used?

The label describes once-weekly subcutaneous injection starting at 2.5 mg. Steps of 2.5 mg follow, no faster than every 4 weeks, to a maintenance of 5 to 15 mg ¹⁰. As reported on forums, gray-market vials are reconstituted and dosed in insulin-syringe units to mirror that ladder. Descriptive only. Convention, not guidance.

How long does Tirzepatide take to work?

Escalation to the top dose takes at least 20 weeks by label ¹⁰. In SURMOUNT-1 the curves separated within the first weeks and ran to 20.9% down at week 72 on 15 mg ¹. SURMOUNT-4 answers the other direction: stop, and most of the loss reverses within a year ⁸.

Is Tirzepatide an approved drug?

Yes, for specific indications. An approval attaches to a named indication, a named dose and a manufactured product. It does not extend to a research-market vial, an off-label goal, or a dose worked out on a forum.

On our index it is graded approved on clinical evidence and very high on community adoption, and those two are rated separately on purpose.

Is Tirzepatide stronger than Semaglutide?

For weight and glycemia at trial doses, the head-to-head record says yes. SURMOUNT-5, an RCT of 751 adults, found 20.2% vs 13.7% lost at 72 weeks ².

SURPASS-2 found HbA1c down 2.30 vs 1.86 points against semaglutide 1 mg ³. Cardiovascular outcomes are the open front: against dulaglutide, tirzepatide proved noninferior, not superior ⁹.

References

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity [SURMOUNT-1]. N Engl J Med. 2022. PMID 35658024
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity [SURMOUNT-5]. N Engl J Med. 2025. PMID 40353578
Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes [SURPASS-2]. N Engl J Med. 2021. PMID 34170647
Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity [SURMOUNT-OSA]. N Engl J Med. 2024. PMID 38912654
Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity [SUMMIT]. N Engl J Med. 2025. PMID 39555826
Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis [SYNERGY-NASH]. N Engl J Med. 2024. PMID 38856224
Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID 39996356
Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID 38078870
Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes [SURPASS-CVOT]. N Engl J Med. 2025. PMID 41406444
Zepbound [tirzepatide] Prescribing Information. Eli Lilly. 2026. dailymed.nlm.nih.gov

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.